biological response modifier


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.

modifier

 [mod´ĭ-fi-er]
1. an agent or method that causes something else to change.
biologic response modifier (BRM) (biological response modifier) a method or agent, such as a cytokine, monoclonal antibody, or vaccine, that alters host-tumor interaction. This is usually accomplished by amplifying the antitumor mechanisms of the immune system, but it also may be effected by mechanisms that affect host or tumor cell characteristics, either directly or indirectly. Called also biomodulator.
problem modifier on level three of the problem classification scheme of the omaha system, either of the two sets of terms used in conjunction with client problems, allowing the nurse to identify ownership of the problem and its degree of severity in relation to client interest, risk factors, and signs or symptoms.

biological response modifier

n.
A substance, such as interferon, that is produced naturally or manufactured as a drug designed to strengthen, direct, or restore the body's immune response against infection or cancer.

biological response modifier

Any of a broad family of biomolecules that up- or down-regulate, or restore immune responsiveness, which are generated after T cells recognise an antigen present on the surface of a self-antigen-presenting cell which, once activated, produce multiple cytokines.
 
Types of BRMs
Interferons, interleukins, colony-stimulating factors, TNFs, B-cell growth factor, B-cell differentiating factors, eosinophil chemotactic factor, lymphotoxin, macrophage chemotactic factor, macrophage activating factor, macrophage inhibiting factor, osteoclast-activating factor, and others.

Therapeutic effects of BRMs
• Regulation and/or increased immune response;
• Cytotoxic or cytostatic activity against tumour cells;
• Inhibition of metastasis or cell maturation;
• Stimulation of BM stem cells, required for recuperation from cytotoxic insult secondary to chemotherapy.

biological response modifier

Immunology Any of a broad family of natural or synthetic molecules that up- or down-regulate, or restore immune responsiveness Types of BRMs Interferons, ILs, CSFs, TNFs, B-cell growth factor, B-cell differentiating factors, eosinophil chemotactic factor, lymphotoxin, macrophage chemotactic factor, macrophage activating factor, macrophage inhibiting factor, osteoclast-activating factor, and others; BRMs are generated after a T cell recognizes an antigen present on the surface of a self antigen-presenting cell which, once activated, produces a multiple lymphokines–cytokines Therapeutic effects of BRMs
1. Regulation and/or increased immune response;.
2. Cytotoxic or cytostatic activity against tumor cells;.
3. Inhibition of metastasis, or cell maturation;.
4. Stimulation of BM stem cells, required for recuperation from cytotoxic insult secondary to chemotherapy. See B cell, Colony-stimulating factor, Interferon, Interleukin, T cell, Tumor necrosis factor.
References in periodicals archive ?
Although biological response modifiers are toxic in many cases, researchers are not sure whether those toxic side effects are due to some property of the drugs themselves or to the interferon production they induce.
The concept of using double-stranded RNA as biological response modifiers started several years ago when Merck Sharp and Dohme of West Point, Pa.
Such a strategy may be vital if biological response modifiers are ever to be used routinely in clincal settings, Levy says.
Biological response modifiers may also play a role in knocking out tumors before they get too large.
He has found that the sex life of feamle mice is important to whether or not their immune systems respond to biological response modifiers.
It differs from the other double-stranded RNA biological response modifiers in that when the drug is made, it is treated so that it's not perfectly helical throughout its entire length.
The report focuses primarily on the class of rheumatoid arthritis therapeutics known as the biological response modifiers (BRMs).
According to The Global Market for Adjunctive Therapies in Cancer 2005 revenues for therapies addressing nausea, anemia, pain, and infections, among others, exceeded $17 billion while between 2003 and 2005, the market grew by nearly 15%, primarily due to strong sales of biological response modifiers, and nausea, emesis, and breakthrough pain management therapies.
Budzynski has had an accomplished and multifaceted scientific career in the research and discovery of biological response modifiers, vaccines, monoclonals and cytotoxic drugs.

Full browser ?